PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) – 1986

The medicine is dispensed with a doctor's prescription only

Voranigo 10 mg film-coated tablets
Voranigo 40 mg film-coated tablets

The active ingredient and its quantity

Voranigo 10 mg film-coated tablets

Each tablet contains vorasidenib 10 mg

Voranigo 40 mg film-coated tablets

Each tablet contains vorasidenib 40 mg

Inactive ingredients and allergens – see section 6 **"Additional information".** See also **"Important information about some of the ingredients of the medicine"** in section 2.

Read the entire leaflet carefully before using the medicine. This leaflet contains concise information about the medicine. If you have additional questions, refer to the doctor or the pharmacist.

This medicine has been prescribed for treatment of your illness. Do not pass it on to others. It may harm them even if it seems to you that their illness is similar.

1. WHAT IS THE MEDICINE INTENDED FOR?

Voranigo is intended for the treatment of adult and pediatric patients 12 years old and above with grade 2 oligodendroglioma or astrocytoma (certain types of brain tumors) that express an isocitrate dehydrogenase 1 (**IDH1**) or isocitrate dehydrogenase 2 (**IDH2**) mutation, following surgical intervention including a biopsy, sub-total resection of the tumor or gross total resection of the tumor.

Therapeutic class: IDH1 and IDH2 inhibitors.

2. BEFORE USING THE MEDICINE

Do not use the medicine if:

- You are sensitive (allergic) to the active ingredient (vorasidenib) or to any of the other ingredients this medicine contains (see section 6 **"Additional information"**).

Special warnings regarding the use of the medicine

Before treatment with Voranigo, tell the doctor if:

- You have liver problems
- You have kidney problems or are being treated with dialysis
- You smoke tobacco

Smoking:

Consult a doctor if you smoke tobacco. Smoking tobacco while using Voranigo may decrease the concentrations of the medicine in the blood and thus decrease its effectiveness.

Children and adolescents:

The safety and efficacy of Voranigo have not been established in children up to the age of 12 years.

Tests and follow-up
The doctor will perform blood chemistry and liver function blood tests before and during treatment with Voranigo.

Drug interactions
If you are taking or have recently taken other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or the pharmacist. Voranigo may affect the way medicines work and other medicines may affect the way Voranigo works.

Strong or moderate CYP1A2 inhibitors
Co-administration of Voranigo with medicines that are strong or moderate inhibitors of the CYP1A2 enzyme (such as: ciprofloxacin, fluvoxamine) may increase the concentration of Voranigo in the blood, and thus may increase the risk of side effects. The doctor will determine whether co-administration of Voranigo with these medicines should be avoided. If co-administration of Voranigo with these medicines cannot be avoided, the doctor will monitor the side effects and, if necessary, will change the dosage of Voranigo.

Moderate CYP1A2 inducers
Co-administration of Voranigo with medicines that are moderate inducers of the CYP1A2 enzyme (such as: rifampicin, phenytoin) may decrease the concentration of Voranigo in the blood and thus may decrease its anti-cancer activity. Avoid co-administration of Voranigo with these medicines.

CYP3A substrates
Co-administration of Voranigo with medicines that are substrates of enzymes of the CYP3A group may decrease their concentration in the blood and thus decrease their effect.

Hormonal contraceptives
Voranigo may affect the way hormonal contraceptives work and decrease their effectiveness, and also lead to an increase in breakthrough bleeding (see also "**Pregnancy, breastfeeding and fertility**" in section 2).

Use of the medicine and food
Voranigo may be taken with or without food.

Pregnancy, breastfeeding and fertility
If you are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed, refer to the doctor before using the medicine. Voranigo may cause harm to the fetus.

Women of childbearing age
- The doctor will perform a pregnancy test before starting treatment with Voranigo.
- You should use appropriate nonhormonal contraceptives during treatment with Voranigo and for 3 months after taking the last dose. Voranigo may affect the way hormonal contraceptives work and decrease their effectiveness (see subsection **"Drug interactions"** in section 2). Consult your doctor regarding appropriate contraceptives that are suitable for you during treatment with Voranigo.
- Refer to the doctor immediately if you become pregnant or if you think you are pregnant during treatment with Voranigo.

Men treated with Voranigo who are partners of women of childbearing age
- You should use appropriate contraceptives during treatment with Voranigo and for 3 months after the last dose.
- Refer to the doctor immediately if your partner becomes pregnant or thinks she is pregnant during treatment with Voranigo.

Breastfeeding
It is not known whether Voranigo passes into breast milk or whether it affects the breastfeeding baby or milk production. **Do not** breastfeed during treatment with Voranigo and for 2 months after taking the last dose.

Fertility
Voranigo may impair fertility in women and men and thus affect their ability to have children.

Driving and operating machinery
You should bear in mind that the treatment with Voranigo may make you feel tired or weak. Exercise caution when driving or operating machinery.

Important information about some of the ingredients of the medicine
The medicine contains lactose monohydrate. If you have been told by your doctor that you have intolerance to some sugars, refer to the doctor before taking this medicine.

3. HOW SHOULD YOU USE THE MEDICINE?

Always use the medicine according to the doctor's instructions. Check with the doctor or pharmacist if you are uncertain about the dosage or how to use the medicine. The dosage and treatment regimen will be determined only by the doctor.

The generally accepted dosage is:
Adults:
One tablet of Voranigo 40 mg, once a day.
Children 12 years of age and above:

- Patients weighing 40 kg and more: one tablet of Voranigo 40 mg, once a day.
- Patients weighing less than 40 kg: 20 mg (2 tablets of Voranigo 10 mg), once a day.

How to take the medicine
Swallow the tablet whole with a glass of water. Voranigo may be taken with or without food.
Do not halve, crush or chew the tablet.
Take Voranigo once a day, at about the same time.

Do not exceed the recommended dose.

If you accidentally took a higher dosage
If you took an overdose or if a child accidentally swallowed this medicine, go to the doctor or to a hospital emergency room immediately and take the package of the medicine with you.

If you forgot to take the medicine
If you forgot to take the medicine and **less than 6 hours** have passed from the scheduled time, take the missed dose immediately. If **more than 6 hours** have passed, skip the daily dose and take the next dose at the scheduled time.

If you vomit after taking Voranigo, **do not** take another dose. Take the next dose on the following day, at the scheduled time.

If you stop taking the medicine
Do not change the dosage or discontinue taking the medicine without consulting the doctor.

Follow the treatment as recommended by the doctor. Even if there is an improvement in your health condition, do not stop treatment with the medicine without consulting the doctor.

Do not take medicines in the dark! Check the label and the dose every time you take a medicine. Wear glasses if you need them.

If you have any other questions regarding use of the medicine, consult the doctor or the pharmacist.

4. SIDE EFFECTS

As with any medicine, use of this medicine may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not experience any of them.

Liver problems

During the treatment with Voranigo, there may be changes in liver function blood tests, which may be severe. This can lead to liver failure, destruction of liver tissue and autoimmune hepatitis. The doctor will perform blood tests to check your liver function before and during treatment with Voranigo. **Tell the doctor immediately if you develop any of the following signs or symptoms of liver problems:**

- Yellowing of the skin or the whites of the eyes (jaundice)
- Dark (tea-colored) urine
- Lack of appetite
- Pain in the upper right area of the abdomen
- Feeling weak or excessive fatigue

Additional side effects:

Very common side effects (effects that occur in more than one user out of ten)

- Elevated liver enzyme levels in the blood (alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT))
- Lack of energy, fatigue
- Headache
- Covid-19
- Muscle pain or stiffness
- Diarrhea
- Increase in blood potassium levels
- Nausea
- Seizures
- Decreased levels of white blood cells (leukocytes)
- Decreased levels of white blood cells called neutrophils
- Constipation
- Abdominal pain
- Increased levels of hemoglobin in the blood
- Decreased levels of platelets in the blood
- Decreased levels of white blood cells called lymphocytes
- Increased creatinine levels in the blood

Common side effects (effects that occur in 1-10 users out of 100)

- Increased blood glucose levels
- Decreased blood calcium levels
- Increased levels of alkaline phosphatase (ALP) in the blood
- Decreased appetite
- Decreased levels of phosphate in the blood

The doctor may change your dosage, temporarily or completely discontinue the treatment with Voranigo if you experience certain side effects.

If a side effect occurs, if one of the side effects worsens, or if you suffer from a side effect not mentioned in this leaflet, consult your doctor.

Reporting of side effects
Side effects may be reported to the Ministry of Health by clicking on the link "Report side effects due to medicinal treatment" found on the Ministry of Health website homepage (www.health.gov.il), which will direct you to the online form for reporting side effects, or by clicking on the following link: https://sideeffects.health.gov.il

5. HOW TO STORE THE MEDICINE?

Avoid poisoning! This medicine and any other medicine must be kept in a closed place out of the reach and sight of children and/or infants to avoid poisoning. Do not induce vomiting without an explicit instruction from the doctor.

Do not use the medicine after the expiry date (exp. date) stated on the package. The expiry date refers to the last day of that month.

Storage conditions
Store below 30°C. After opening for the first time, the medicine can be used for 60 days and no later than the expiry date appearing on the package, store the bottle below 30°C.

6. ADDITIONAL INFORMATION

In addition to the active ingredient the medicine also contains:
Tablet core:
microcrystalline cellulose, silicified microcrystalline cellulose, croscarmellose sodium, magnesium stearate and sodium lauryl sulfate.
Tablet coating:
HPMC 2910/hypromellose, titanium dioxide, lactose monohydrate and macrogol/PEG 4000.
The black imprint on the tablet:
ferrosoferric oxide/black iron oxide, propylene glycol and HPMC 2910/hypromellose.

What does the medicine look like and what are the contents of the package?
Voranigo 10 mg film-coated tablets
White to cream colored, round film-coated tablet, imprinted with "10" in black ink on one side.
Voranigo 40 mg film-coated tablets
White to cream colored, oblong film-coated tablet, imprinted with "40" in black ink on one side.

Voranigo tablets are packed in a bottle with a child-resistant cap. The bottle contains 30 tablets and 3 desiccants. **Do not** take the desiccants out of the bottle. **Do not** swallow the desiccants.

License holder and address
Medison Pharma Ltd.
10 Hashiloach St., P.O. Box 7090, Petach Tikva

Name and address of the manufacturer
LES LABORATOIRES SERVIER
50 rue Carnot, 92284 Suresnes Cedex, France

Approved in March 2025.

Registration number of the medicine in the national drug registry of the Ministry of Health
Voranigo 10 mg film-coated tablets: 178-23-37980-99
Voranigo 40 mg film-coated tablets: 178-24-37981-99